Identification of miR‑25‑3p as a tumor biomarker: Regulation of cellular functions via TOB1 in breast cancer

Zhao,Tianyi; Meng,Wenjing; Chin,Yenlie; Gao,Lili; Yang,Xiyue; Sun,Shuangyu; Pan,Xingfang; He,Lihong

doi:10.3892/mmr.2021.12045

Identification of miR‑25‑3p as a tumor biomarker: Regulation of cellular functions via TOB1 in breast cancer

Authors:
- Tianyi Zhao
- Wenjing Meng
- Yenlie Chin
- Lili Gao
- Xiyue Yang
- Shuangyu Sun
- Xingfang Pan
- Lihong He
View Affiliations

Affiliations: Institute of Basic Research In Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China, Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Integrated Traditional Chinese Medicine and Western Medicine Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Traditional Chinese Medicine, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300052, P.R. China, School of Acupuncture and Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China
Published online on: March 26, 2021 https://doi.org/10.3892/mmr.2021.12045
Article Number: 406
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common cancer in women and is one of the three most common malignancies worldwide. Serum microRNAs (miRNAs/miRs) are ideal biomarkers for tumor diagnosis and prognosis due to their specific biological characteristics. In several different types of cancer, miRNAs are associated with cell migration and invasion. In the present study, miR‑25‑3p expression levels were detected in tissue and serum samples derived from patients with breast cancer, and the diagnostic and prognostic value of miR‑25‑3p in breast cancer was evaluated. Cellular function assays were performed to evaluate the role of miR‑25‑3p in breast cancer. Moreover, dual‑luciferase reporter assays and western blotting were performed to investigate the target of miR‑25‑3p. miR‑25‑3p expression was upregulated in breast cancer tissue and serum samples compared with normal breast tissue and serum samples. Patients with breast cancer with high serum miR‑25‑3p levels were more likely to have lymph node metastasis compared with those with low serum miR‑25‑3p levels. The area under the curve for miR‑25‑3p in the diagnosis of breast cancer was 0.748, with 57.1% sensitivity and 95.0% specificity. Moreover, the Kaplan‑Meier survival curves demonstrated that patients with breast cancer with a low expression of serum miR‑25‑3p had a higher overall survival rate compared with patients with a high serum miR‑25‑3p expression. miR‑25‑3p knockdown suppressed breast cancer cell proliferation and invasion, and transducer of ERBB2, 1 (TOB1) was identified as a potential target gene regulated by miR‑25‑3p. Therefore, the present study suggested that miR‑25‑3p regulated cellular functions via TOB1 in breast cancer; therefore, miR‑25‑3p may serve as a breast cancer biomarker.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Bray F, McCarron P and Parkin DM: The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 6:229–239. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
5	Pogoda K, Niwińska A, Murawska M and Pieńkowski T: Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 30:3882013. View Article : Google Scholar : PubMed/NCBI
6	Liang F, Liang H, Li Z and Huang P: JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. Int Immunopharmacol. 86:1067062020. View Article : Google Scholar : PubMed/NCBI
7	Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I and Haakensen VD: Profiling of microRNAs in tumor interstitial fluid of breast tumors-a novel resource to identify biomarkers for prognostic classification and detection of cancer. Mol Oncol. 11:220–234. 2017. View Article : Google Scholar : PubMed/NCBI
8	Madhavan D, Cuk K, Burwinkel B and Yang R: Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 4:1162013. View Article : Google Scholar : PubMed/NCBI
9	Christou N, Meyer J, Popeskou S, David V, Toso C, Buchs N, Liot E, Robert J, Ris F and Mathonnet M: Circulating tumour cells, circulating tumour DNA and circulating tumour miRNA in blood assays in the different steps of colorectal cancer management, a review of the evidence in 2019. Biomed Res Int. 2019:59530362019. View Article : Google Scholar : PubMed/NCBI
10	Zhang K, Wu X, Wang J, Lopez J, Zhou W, Yang L, Wang SE, Raz DJ and Kim JY: Circulating miRNA profile in esophageal adenocarcinoma. Am J Cancer Res. 6:2713–2721. 2016.PubMed/NCBI
11	Liu X, Zhang H, Qin S, Wang Q, Yang X and Wang K: Optical fiber amplifier for quantitative and sensitive point-of-care testing of myoglobin and miRNA-141. Biosens Bioelectron. 129:87–92. 2019. View Article : Google Scholar : PubMed/NCBI
12	Imaoka H, Toiyama Y, Fujikawa H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, et al: Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol. 27:1879–1886. 2016. View Article : Google Scholar : PubMed/NCBI
13	Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
14	Bhagirath D, Yang TL, Bucay N, Sekhon K, Majid S, Shahryari V, Dahiya R, Tanaka Y and Saini S: microRNA-1246 Is an exosomal biomarker for aggressive prostate cancer. Cancer Res. 78:1833–1844. 2018. View Article : Google Scholar : PubMed/NCBI
15	Li Z, Zhou L, Lin C, Pan X, Xie J, Zhao L, Quan J, Xu J, Guan X, Xu W, et al: miR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer. Life Sci. 209:15–23. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhao C, Ling X, Li X, Hou X and Zhao D: MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 26:817–825. 2019. View Article : Google Scholar : PubMed/NCBI
17	Lee HS, Kundu J, Kim RN and Shin YK: Transducer of ERBB2.1 (TOB1) as a tumor suppressor: A mechanistic perspective. Int J Mol Sci. 16:29815–29828. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kundu J, Wahab SM, Kundu JK, Choi YL, Erkin OC, Lee HS, Park SG and Shin YK: Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β-catenin signaling. Int J Oncol. 41:839–848. 2012. View Article : Google Scholar : PubMed/NCBI
19	Jiao Y, Sun KK, Zhao L, Xu JY, Wang LL and Fan SJ: Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin. 33:250–260. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wu D, Zhou W, Wang S, Zhou Z, Wang S and Chen L: Tob1 enhances radiosensitivity of breast cancer cells involving the JNK and p38 pathways. Cell Biol Int. 39:1425–1430. 2015. View Article : Google Scholar : PubMed/NCBI
21	Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, et al: The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 8:21609–21625. 2017. View Article : Google Scholar : PubMed/NCBI
22	Sárközy M, Kahán Z and Csont T: A myriad of roles of miR-25 in health and disease. Oncotarget. 9:21580–21612. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wang X, Meng X, Li H, Liu W, Shen S and Gao Z: MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol. 16:954–958. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
25	Jia Y, Lu H, Wang C, Wang J and Zhang C, Wang F and Zhang C: miR-25 is upregulated before the occurrence of esophageal squamous cell carcinoma. Am J Transl Res. 9:4458–4469. 2017.PubMed/NCBI
26	Chang JT, Wang F, Chapin W and Huang RS: Identification of MicroRNAs as breast cancer prognosis markers through the cancer genome atlas. PLoS One. 11:e01682842016. View Article : Google Scholar : PubMed/NCBI
27	Chen H, Pan H, Qian Y, Zhou W and Liu X: miR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 17:42018. View Article : Google Scholar : PubMed/NCBI
28	Zou X, Xia T, Li M, Wang T, Liu P, Zhou X, Huang Z and Zhu W: MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis. Cancer Biomark. 30:41–53. 2021. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Dyer BW, Ferrer FA, Klinedinst DK and Rodriguez R: A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal Biochem. 282:158–161. 2000. View Article : Google Scholar : PubMed/NCBI
31	Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF and Atkins JF: A dual-luciferase reporter system for studying recoding signals. RNA. 4:479–486. 1998.PubMed/NCBI
32	Cortez MA, Welsh JW and Calin GA: Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 195:151–161. 2012. View Article : Google Scholar : PubMed/NCBI
33	Mens MMJ and Ghanbari M: Cell cycle regulation of stem cells by MicroRNAs. Stem Cell Rev Rep. 14:309–322. 2018. View Article : Google Scholar : PubMed/NCBI
34	Qi Y, Wang X, Kong X, Zhai J, Fang Y, Guan X and Wang J: Expression signatures and roles of microRNAs in inflammatory breast cancer. Cancer Cell Int. 19:232019. View Article : Google Scholar : PubMed/NCBI
35	Li Z, Lin C, Zhao L, Zhou L, Pan X, Quan J, Peng X, Li W, Li H, Xu J, et al: Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer. Biomed Pharmacother. 105:461–469. 2018. View Article : Google Scholar : PubMed/NCBI
36	Olejniczak M, Kotowska-Zimmer A and Krzyzosiak W: Stress-induced changes in miRNA biogenesis and functioning. Cell Mol Life Sci. 75:177–191. 2018. View Article : Google Scholar : PubMed/NCBI
37	Singh SK, Pal Bhadra M, Girschick HJ and Bhadra U: MicroRNAs-micro in size but macro in function. FEBS J. 275:4929–4944. 2008. View Article : Google Scholar : PubMed/NCBI
38	Armand-Labit V and Pradines A: Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts. 8:61–81. 2017. View Article : Google Scholar : PubMed/NCBI
39	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 10:10513–10518. 2008. View Article : Google Scholar
40	Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, Xu N and Xu B: Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One. 9:e1048702014. View Article : Google Scholar : PubMed/NCBI
41	Shen L, Wan Z, Ma Y, Wu L, Liu F, Zang H and Xin S: The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers. Tumour Biol. 36:1993–2005. 2015. View Article : Google Scholar : PubMed/NCBI
42	Gruszka R and Zakrzewska M: The oncogenic relevance of miR-17-92 cluster and its paralogous miR-106b-25 and miR-106a-363 clusters in brain tumors. Int J Mol Sci. 19:8792018. View Article : Google Scholar
43	Wang C, Wang X, Su Z, Fei H, Liu X and Pan Q: miR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244. 2015. View Article : Google Scholar : PubMed/NCBI
44	Hua Y, Zhao K, Tao G, Dai C and Su Y: miR-25 promotes metastasis via targeting FBXW7 in esophageal squamous cell carcinoma. Oncol Rep. 38:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI
45	Fujiwara T, Uotani K, Yoshida A, Morita T, Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al: Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget. 8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
46	Deng T, Yuan Y, Zhang C, Zhang C, Yao W, Wang C, Liu R and Ba Y: Identification of circulating miR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell Physiol Biochem. 39:1716–1722. 2016. View Article : Google Scholar : PubMed/NCBI
47	Wang X, Wu X, Yan L and Shao J: Serum miR-103 as a potential diagnostic biomarker for breast cancer. Nan Fang Yi Ke Da Xue Xue Bao. 32:631–634. 2012.(In Chinese). PubMed/NCBI
48	Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL and Zhang YK: Serum microRNA-195 is down-regulated in breast cancer: A potential marker for the diagnosis of breast cancer. Mol Biol Rep. 41:5913–5922. 2014. View Article : Google Scholar : PubMed/NCBI
49	Li S, Yang X, Yang J, Zhen J and Zhang D: Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: A systematic review and meta-analysis. Clin Exp Med. 16:29–35. 2016. View Article : Google Scholar : PubMed/NCBI
50	Jinling W, Sijing S, Jie Z and Guinian W: Prognostic value of circulating microRNA-21 for breast cancer: A systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 45:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
51	Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai CY, Hou MF, Lee JN, Wu DC, Wang SC and Tsai EM: miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 6:494–509. 2015. View Article : Google Scholar : PubMed/NCBI
52	Li J, Song ZJ, Wang YY, Yin Y, Liu Y and Nan X: Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer. Genet Mol Res. 152016.doi: 10.4238/gmr.15038338.
53	Lin S, Zhu Q, Xu Y, Liu H, Zhang J, Xu J, Wang H, Sang Q, Xing Q and Fan J: The role of the TOB1 gene in growth suppression of hepatocellular carcinoma. Oncol Lett. 4:981–987. 2012. View Article : Google Scholar : PubMed/NCBI
54	O'Malley S, Su H, Zhang T, Ng C, Ge H and Tang CK: TOB suppresses breast cancer tumorigenesis. Int J Cancer. 125:1805–1813. 2009. View Article : Google Scholar : PubMed/NCBI
55	Guo H, Ji F, Zhao X, Yang X, He J, Huang L and Zhang Y: MicroRNA-371a-3p promotes progression of gastric cancer by targeting TOB1. Cancer Lett. 443:179–188. 2019. View Article : Google Scholar : PubMed/NCBI